SCHEMBL4775728

SCHEMBL4775728

COC(=O)c1ccc(Oc2cc(Cl)ccc2OC)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
HPGD P15428 1/20 0.48
TDP1 Q9NUW8 2/20 0.46
SLC9A1 P19634 1/20 0.45
POLB P06746 1/20 0.44
GFER P55789 1/20 0.44
KDM4E B2RXH2 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774815 0.86 POLB (0.44) ALDH1A1HPGDPOLBGFERKDM4E
SCHEMBL14034917 0.84 NPC1 (0.44) ALDH1A1HPGDTDP1KDM4EKMT2A
SCHEMBL4924601 0.83 PTGER1 (0.52) KMT2AMEN1SMN1; SMN2NPC1MAPK1
SCHEMBL4944323 0.78 ALDH1A1 (0.77) ALDH1A1HPGDTDP1SLC9A1KDM4E
SCHEMBL19442049 0.74 HTT (0.58) ALDH1A1HPGDPOLBKDM4EKMT2A
SCHEMBL27145822 0.72 ALDH1A1 (0.47) ALDH1A1POLBGFERKMT2AMEN1
SCHEMBL28105591 0.72 CA1 (0.50) ALDH1A1HPGDKDM4EKMT2AMEN1
SCHEMBL14019050 0.72 HTT (0.40) ALDH1A1POLBKDM4EKMT2AMEN1
SCHEMBL25002899 0.70 ALDH1A1 (0.65) ALDH1A1HPGDSLC9A1KDM4EMAPT
SCHEMBL1095516 0.70 MEN1 (0.64) ALDH1A1KMT2AMEN1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1874749-A1 FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2008-01-09 EP disclosed
WO-2006114272-A1 FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists PTGER1, PTGER2, PTGER3 ALDH1A1 1015/4885HPGD 439/4885TDP1 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.